Frelinger Andrew L, Gerrits Anja J, Garner Allen L, Torres Andrew S, Caiafa Antonio, Morton Christine A, Berny-Lang Michelle A, Carmichael Sabrina L, Neculaes V Bogdan, Michelson Alan D
Center for Platelet Research Studies, Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
School of Nuclear Engineering, Purdue University, West Lafayette, Indiana, United States of America.
PLoS One. 2016 Aug 24;11(8):e0160933. doi: 10.1371/journal.pone.0160933. eCollection 2016.
Activated autologous platelet-rich plasma (PRP) used in therapeutic wound healing applications is poorly characterized and standardized. Using pulsed electric fields (PEF) to activate platelets may reduce variability and eliminate complications associated with the use of bovine thrombin. We previously reported that exposing PRP to sub-microsecond duration, high electric field (SMHEF) pulses generates a greater number of platelet-derived microparticles, increased expression of prothrombotic platelet surfaces, and differential release of growth factors compared to thrombin. Moreover, the platelet releasate produced by SMHEF pulses induced greater cell proliferation than plasma.
To determine whether sub-microsecond duration, low electric field (SMLEF) bipolar pulses results in differential activation of PRP compared to SMHEF, with respect to profiles of activation markers, growth factor release, and cell proliferation capacity.
PRP activation by SMLEF bipolar pulses was compared to SMHEF pulses and bovine thrombin. PRP was prepared using the Harvest SmartPreP2 System from acid citrate dextrose anticoagulated healthy donor blood. PEF activation by either SMHEF or SMLEF pulses was performed using a standard electroporation cuvette preloaded with CaCl2 and a prototype instrument designed to take into account the electrical properties of PRP. Flow cytometry was used to assess platelet surface P-selectin expression, and annexin V binding. Platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), endothelial growth factor (EGF) and platelet factor 4 (PF4), and were measured by ELISA. The ability of supernatants to stimulate proliferation of human epithelial cells in culture was also evaluated. Controls included vehicle-treated, unactivated PRP and PRP with 10 mM CaCl2 activated with 1 U/mL bovine thrombin.
PRP activated with SMLEF bipolar pulses or thrombin had similar light scatter profiles, consistent with the presence of platelet-derived microparticles, platelets, and platelet aggregates whereas SMHEF pulses primarily resulted in platelet-derived microparticles. Microparticles and platelets in PRP activated with SMLEF bipolar pulses had significantly lower annexin V-positivity than those following SMHEF activation. In contrast, the % P-selectin positivity and surface P-selectin expression (MFI) for platelets and microparticles in SMLEF bipolar pulse activated PRP was significantly higher than that in SMHEF-activated PRP, but not significantly different from that produced by thrombin activation. Higher levels of EGF were observed following either SMLEF bipolar pulses or SMHEF pulses of PRP than after bovine thrombin activation while VEGF, PDGF, and PF4 levels were similar with all three activating conditions. Cell proliferation was significantly increased by releasates of both SMLEF bipolar pulse and SMHEF pulse activated PRP compared to plasma alone.
PEF activation of PRP at bipolar low vs. monopolar high field strength results in differential platelet-derived microparticle production and activation of platelet surface procoagulant markers while inducing similar release of growth factors and similar capacity to induce cell proliferation. Stimulation of PRP with SMLEF bipolar pulses is gentler than SMHEF pulses, resulting in less platelet microparticle generation but with overall activation levels similar to that obtained with thrombin. These results suggest that PEF provides the means to alter, in a controlled fashion, PRP properties thereby enabling evaluation of their effects on wound healing and clinical outcomes.
用于治疗性伤口愈合的活化自体富血小板血浆(PRP)的特性和标准化程度较低。使用脉冲电场(PEF)激活血小板可能会降低变异性,并消除与使用牛凝血酶相关的并发症。我们之前报道,与凝血酶相比,将PRP暴露于亚微秒持续时间的高电场(SMHEF)脉冲会产生更多数量的血小板衍生微粒,增加促血栓形成血小板表面的表达,并使生长因子有不同程度的释放。此外,SMHEF脉冲产生的血小板释放物比血浆诱导的细胞增殖更多。
确定与SMHEF相比,亚微秒持续时间的低电场(SMLEF)双极脉冲是否会导致PRP的不同激活,涉及激活标志物谱、生长因子释放和细胞增殖能力。
将SMLEF双极脉冲激活PRP与SMHEF脉冲和牛凝血酶进行比较。使用Harvest SmartPreP2系统从用枸橼酸葡萄糖抗凝的健康供体血液中制备PRP。使用预装有CaCl2的标准电穿孔比色皿和考虑到PRP电学特性而设计的原型仪器,通过SMHEF或SMLEF脉冲进行PEF激活。使用流式细胞术评估血小板表面P-选择素表达和膜联蛋白V结合情况。通过酶联免疫吸附测定法测量血小板衍生生长因子(PDGF)、血管内皮生长因子(VEGF)、内皮生长因子(EGF)和血小板因子4(PF4)。还评估了上清液刺激培养中的人上皮细胞增殖的能力。对照包括未处理的未激活PRP和用1 U/mL牛凝血酶激活的含10 mM CaCl2的PRP。
用SMLEF双极脉冲或凝血酶激活的PRP具有相似的光散射谱,这与存在血小板衍生微粒、血小板和血小板聚集体一致,而SMHEF脉冲主要产生血小板衍生微粒。用SMLEF双极脉冲激活的PRP中的微粒和血小板的膜联蛋白V阳性率明显低于SMHEF激活后的情况。相反,SMLEF双极脉冲激活的PRP中血小板和微粒的P-选择素阳性百分比和表面P-选择素表达(平均荧光强度)明显高于SMHEF激活的PRP,但与凝血酶激活产生的情况无显著差异。与牛凝血酶激活后相比,PRP经SMLEF双极脉冲或SMHEF脉冲处理后观察到更高水平的EGF,而在所有三种激活条件下VEGF、PDGF和PF4水平相似。与单独的血浆相比,SMLEF双极脉冲和SMHEF脉冲激活的PRP释放物均显著增加细胞增殖。
在双极低场强与单极高场强下,PEF激活PRP会导致不同的血小板衍生微粒产生和血小板表面促凝血标志物的激活,同时诱导相似的生长因子释放和相似的诱导细胞增殖能力。用SMLEF双极脉冲刺激PRP比SMHEF脉冲更温和,导致产生的血小板微粒更少,但总体激活水平与凝血酶激活获得的水平相似。这些结果表明,PEF提供了一种以可控方式改变PRP特性的手段,从而能够评估其对伤口愈合和临床结果的影响。